Semaglutide shows antifibrotic signal in advanced MASH trial

Semaglutide posts a notable result in a hard-to-treat liver disease

Semaglutide, a GLP-1 medicine already widely used in diabetes and obesity care, may also help patients with advanced metabolic dysfunction-associated steatohepatitis, or MASH, according to results from a large international clinical trial reported by researchers at the University of California San Diego School of Medicine.

The study, published July 15, 2026 in The Lancet Gastroenterology & Hepatology, focused on one of the most difficult problems in fatty liver disease: reversing or reducing fibrosis, the liver scarring that builds as the disease progresses. That scarring is a major driver of long-term risk because it can eventually impair liver function, push patients toward cirrhosis and liver failure, and leave transplantation as the last option.

What makes the new result stand out is the patient population. The Phase 2 trial enrolled about 700 adults with biopsy-confirmed MASH and moderate to advanced liver scarring, including people who had already developed compensated cirrhosis, an early stage of cirrhosis in which the liver is heavily scarred but still functioning.

That matters because treatment options have been especially limited once disease reaches advanced fibrosis or early cirrhosis. In that setting, even incremental evidence of disease modification can carry outsized importance for clinicians and patients.

What the trial tested

The trial was designed around a combination strategy. Researchers evaluated whether pairing semaglutide with zalfermin, an experimental metabolic therapy, could reverse fibrosis more effectively than either medicine alone.

On that main comparison, the combination did not beat placebo. But the study still produced a result that could shape the field: semaglutide by itself showed a statistically significant improvement in liver scarring without worsening the underlying liver inflammation that defines MASH.

According to the source text, that signal was seen even among patients with the most advanced disease in the study, including those with compensated cirrhosis. Senior author Rohit Loomba, chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine, described the finding as the first clinical trial evidence that semaglutide may improve liver fibrosis in advanced MASH, including compensated cirrhosis.

The distinction is important. In liver disease trials, fibrosis and inflammation do not always move in tandem, and an apparent gain in one measure can be offset if the other worsens. The reported outcome here suggests semaglutide may be affecting scarring while avoiding that tradeoff, at least within the conditions measured in this trial.

Why MASH has become a major drug-development target

MASH is a severe form of fatty liver disease tied to metabolic dysfunction. It affects millions of people globally and has become one of the fastest-growing causes of liver failure and liver transplantation. As scar tissue accumulates, the liver’s ability to perform essential metabolic and detoxifying work declines.

That disease burden has turned MASH into one of the most closely watched therapeutic areas in metabolic medicine. Drug developers have pursued multiple approaches aimed at fat metabolism, inflammation, fibrosis, and broader cardiometabolic risk, but advanced-stage disease remains particularly hard to reverse.

Semaglutide has attracted attention because its effects on weight, glucose control, and metabolic health make it a plausible candidate in MASH. The new trial does not establish it as a definitive standard of care for advanced disease, but it strengthens the case that GLP-1-based treatment could have a role beyond diabetes and obesity.

Just as importantly, the result sharpens the strategic question for the next wave of studies: whether future MASH therapy should rely on single agents with broad metabolic effects, or combinations intended to push fibrosis regression further. In this trial, the combination approach did not produce the hoped-for advantage, while the established GLP-1 agent generated the clearer signal.

What this means for patients and the market

For patients, the immediate implication is not that treatment standards have already changed, but that a large unmet need may finally be opening to more credible intervention. People with advanced MASH and early cirrhosis have had few options once fibrosis is entrenched. Evidence that semaglutide may improve scarring in that group could influence future clinical development, regulatory discussions, and prescribing expectations if subsequent studies confirm the effect.

For the broader industry, the finding reinforces how quickly GLP-1 medicines are extending into adjacent disease areas. Drugs first adopted for glycemic control have already expanded into obesity and cardiovascular risk reduction. A meaningful role in advanced liver disease would further widen their clinical and commercial footprint.

At the same time, the study leaves important questions open. The source text does not provide durability data, detailed subgroup outcomes, or long-term clinical endpoints such as progression to liver failure, hospitalization, or transplant avoidance. Those are the measures that will ultimately determine how much disease course is truly altered.

Still, the signal reported here is difficult to ignore. In a field where advanced fibrosis has remained stubbornly resistant to treatment, a statistically significant improvement in scarring without worsening inflammation represents a meaningful development, especially in patients already entering cirrhosis territory.

What to watch next

The next phase for this story will depend on replication, longer follow-up, and how regulators interpret the evidence in advanced MASH populations. If future trials confirm that semaglutide can reliably reduce fibrosis in compensated cirrhosis or severe scarring, the drug could move from being a metabolic adjunct in liver disease to a central therapeutic option.

That would mark a significant shift for hepatology. For years, the field has been defined by rising prevalence, high unmet need, and slow progress in advanced disease. This trial does not close that gap, but it suggests the gap may finally be narrowing.

• The Phase 2 study followed about 700 adults with biopsy-confirmed MASH and moderate to advanced liver scarring.
• Semaglutide alone showed statistically significant improvement in liver scarring without worsening underlying inflammation.
• The combination of semaglutide and zalfermin did not outperform placebo.
• The signal extended to patients with compensated cirrhosis, a group with particularly limited treatment options.

This article is based on reporting by Medical Xpress. Read the original article.